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 Abstract 
Carboxylic acids are ubiquitous in medicinal compounds, such as nonsteroidal anti-
inflammatories, statins, hypertensives, and anticoagulants.  Despite their prolific use, 
unfavorable characteristics such as metabolic instability, poor membrane permeability, 
and toxicity have been associated with this moiety in some instances.  Bioisosteres have 
been employed to attenuate these issues.  However, bioisostere use can alter drug potency 
and disposition.  Recently, our company demonstrated the feasibility of the tetrazolone 
moiety as a carboxylic acid bioisostere for the angiotensin II antagonist telmisartan.  
R941000 (telmisartan-tetrazolone analog) was a potent in vitro inhibitor of angiotensin II 
and possessed a similar disposition to telmisartan.  To the best of our knowledge, no 
studies of the changes in disposition caused by bioisosteric replacement of a carboxylic 
acid with a tetrazolone have been published.  In this work, the disposition of R941000 
was evaluated in Sprague Dawley rats, and in vitro metabolism was conducted using 
human and rat hepatocytes and supplemented microsomes.  Results indicated comparable 
PK parameters for R941000 relative to telmisartan, respectively, bioavailability (64.7% 
vs 59.2%), exposure (2610 ngL/h vs 1850 ngL/h) Clpred (4.51 ml/min vs 7.23 ml/min) 
t1/2 (5.37h vs 3.64 h) and Vss (1.67L/kg vs 1.59L/kg).  Both compounds underwent 
biliary excretion, and glucuronide metabolites were found in rat bile; however, no 
significant glucuronidation was observed in in vitro assays.  Additional studies utilizing 
tetrazolone bioisosteres in other species and classes of compounds are needed to further 
characterize their utility as a carboxylic acid substitute. 
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1 
1.0 Introduction 
 
 Bioisosteres are functional groups consisting of atom(s) that exhibit similar shape, 
volume, and/or electronic properties, and elicit comparable biological responses as the 
chemical moieties they replace.1,2,3,4   Sage use of bioisosteres can be critical for medicinal 
chemists attempting to optimize the pharmacological properties of a chemical scaffold, 
including improved ADME (absorption, distribution, metabolism, excretion) properties 
and safety profile.1,2  Additionally, bioisosteres can generate additional intellectual 
property (IP) space.1  
 Carboxylic acid functional groups are important for many biochemical reactions 
and can be found in endogenous substances such as prostanoids and amino acids.  Due to 
its low pKa, carboxylic acid exists as an ionized species at physiological pH.  This unique 
feature along with its important biological roles (i.e. β-oxidation, elongation of fatty acids 
and prostaglandin synthesis, etc.) allow for carboxylic acid to play a critical part in the 
pharmacophores of many drugs.  Indeed, carboxylic acid can be found in >450 drugs 
marketed today.1  Despite their widespread use in medicinal compounds, carboxylic acids 
can be subject to liabilities such as metabolic instability, poor membrane permeability, 
and toxicity, in some cases.  A variety of bioisosteres have been employed to attenuate 
these liabilities and improve function such as tetrazoles, isothiazoles, and hydroxamic 
acids, to name a few.1  
 While carboxylic acid bioisosteres have been used successfully, use of functional 
group surrogates remains a subtle art.  Replacement of a molecular moiety with an 
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“equivalent” group may result in a pharmacologically inactive compound or molecule 
with dramatically altered ADME behavior.1  It is therefore important to screen 
bioisosteres for changes in potency and disposition.  For these reasons, it is advantageous 
to have a palette of chemical “similars” to work with when optimizing compounds. 
 Recently, our company demonstrated a facile one pot synthesis of tetrazolones 
and postulated their potential suitability as a carboxylic acid substitute due to similarity in 
structure with tetrazoles.  Additionally, the tetrazolone moiety possesses an acidic 
hydrogen with a pKa equivalent to a carboxylic acid and has a planar structure.  A 
telmisartan tetrazolone analog (R941000, see Figure 1) was synthesized and found to 
have excellent potency relative to telmisartan (IC50 = 1.7nM v 5.7nM) respectively, for 
inhibition of AT1 receptor.5  Moreover, R941000 demonstrated comparable ADME 
behavior in Sprague Dawley (SD) rats.  
 
Figure 1.  The chemical structure above depicts R941000 with the tetrazolone moiety circled. 
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 Examples of tetrazolone use in medicinal compounds are sparse, and non-existent 
when assessing changes in drug disposition.  Understanding how various moieties affect 
the ADME characteristics is vital in developing lead compounds that will succeed in a 
clinical setting.  It is the intent of this thesis to evaluate the suitability of tetrazolones, a 
bioisostere for carboxylic acids in terms of disposition, using R941000 as a model 
compound, SD rats as a model pre-clinical species, and cryopreserved hepatocytes and 
microsomes as an in vitro platform to predict human disposition. 
1.1 Drug Disposition: Principles of ADME 
Drug disposition, or ADME, is the study of how a drug behaves once it has been 
administered.6,7  When a drug is taken, it gets absorbed, is distributed throughout the body 
and is eliminated either as the parent drug or metabolite.  Understanding drug disposition 
is critical to proper drug administration, and allows for reasonable estimates of what drug 
concentration will be over time, permitting establishment of a safe and effective dosing 
regimen (See Figure 2).  As can be seen on the right side in Figure 2, the drug 
concentration over time is plotted for an orally administered drug.  The total exposure, 
AUC (area under the curve) is shown along with the therapeutic window, between MTC 
(minimum toxic concentration) and MEC (minimum effective concentration).  Factors 
responsible for drug disposition can be broken down into two interrelated areas of study: 
pharmacokinetics and drug metabolism.  A brief description of each will follow. 
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Figure 2.  An illustration of the ADME behavior of a drug and therapeutic index are shown 
above. 
1.2 Basic Pharmacokinetic Principles 
Pharmacokinetics (PK) is the study of the time course of a drug as it relates to 
ADME principles.6  Since drugs are typically eliminated by circulating in blood through 
organs such as the liver and kidney, taking blood measurements over time can be 
effective in determining the rate of drug elimination and, consequently, the establishment 
of safe dosing regimens.  Additionally, there is often a relationship between drug 
concentration in blood and therapeutic effect, making accurate knowledge of a 
compound’s concentration over time critical for effective dosing. 
Many mathematical models have been used to explain the PK profiles of drugs, 
the simplest of which is described by Equation 1 (for an intravenously [IV] administered 
drug).6 
(1) 𝐶 =
𝐷
𝑉
𝑒
−𝐶𝑙∗𝑡
𝑉 , 𝑜𝑟 𝐶 = 𝐴𝑒−𝑘𝑡  
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Where C is the concentration (in blood or plasma) at any time, D is the dose amount, V is 
the volume of distribution, Cl is clearance, t is time, and k is the elimination rate constant 
(Equation 2) and is usually estimated by determining the slope of the terminal phase of a 
linear graph of concentration over time (see Figure 3).  Cl and V are primary 
pharmacokinetic parameters, which can be used to determine secondary yet important 
factors like drug half-life (Equation 3) and total drug exposure AUC (Equation 4).6 
 
 
Figure 3.  A depiction of the change in drug concentration over time in a linear plot for an IV 
administered drug is shown above.  In the figure both the distributive phase (described by the α 
slope) and the elimination phase (β slope) can be seen. 
(2) 𝑘 =
𝐶𝑙
𝑉
 
(3) t1/2  =
𝐿𝑛(2)
𝐾
 
(4) 𝐴𝑈𝐶 = ∫ 𝐶𝑑𝑡
𝑡
0
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Clearance is one of the most important pharmacokinetic parameters, and describes 
the rate at which a substance is removed from the blood or plasma.6  Due to its simplicity 
and minimal required information, early PK studies often calculate whole body clearance 
by dividing the IV dose by the total IV exposure, AUCIV (Equation 5).  Since IV 
administered drugs are completely absorbed and AUC is the total resultant exposure from 
a dose (D), dividing D over AUC (D = mg/kg AUC = ng/ml/kg*h) results in Cl values of 
ml/h.  Cl incorporates the body’s ability to enzymatically modify and physically remove a 
substance.  Knowing the Cl of a compound is important in establishing its half-life, and 
from there a proper dosing regimen. 
(5)  𝐶𝑙 =
𝐷𝑖𝑣
𝐴𝑈𝐶𝑖𝑣
 
Volume of distribution (V) is the theoretical volume that would be required for an 
administered drug that is evenly distributed to match the measured blood plasma 
concentration.6,8  There are approximately 5 L of blood and 40 L of intracellular fluid in 
an adult 70 kg person.6,8  Compounds with little tissue distribution will remain mostly in 
the body’s central compartment and have a relatively low V, while a drug that highly 
distributes to other tissues will have a high volume of distribution.  V does not represent 
an actual volume; indeed, some drugs have V values exceeding 500 L, far greater than 
the actual volume on any individual.  These large values are often achieved through 
several factors such as transporters actively taking up compound into tissues, or 
nonspecific binding to blood and cellular proteins.6,8    
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While an abstract value, V is important because it affects the systemic 
concentration of a compound and consequently the concentration of drug a receptor or 
metabolizing enzyme will see, thus influencing the degree of drug response and the 
elimination constant, k (see Equations 1-3).  Figure 4 shows the volumes of various 
“compartments” for humans, as well as what constitutes low, medium, and high volume 
drugs. 
 
Figure 4.  The above figure shows the total fluid volume per Kg for humans. Values for tissue, 
total body water, blood, and plasma volumes are given along with a definition of low, 
moderate, or high volume values.8  
Another important PK parameter to consider is the bioavailability of a drug (%F).  
An orally administered drug on the other hand may only be partially dissolved, absorbed 
in the gut with the rest eliminated in the feces, or metabolized before reaching systemic 
circulation.  A common practice in determining the amount of drug absorbed from an oral 
(PO) dose is to normalize the PO dose to the IV dose and divide the oral exposure by the 
intravenous exposure (see Equation 6).6 
(6) %𝐹 = 100 ∗
𝑑𝑜𝑠𝑒𝐼𝑉∗𝐴𝑈𝐶𝑃𝑂
𝑑𝑜𝑠𝑒𝑃𝑂∗𝐴𝑈𝐶𝐼𝑉
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1.3 Drug Metabolism  
Drug metabolism is the study of how xenobiotic transforming enzymes modify 
compounds to expedite their elimination from the body.7,9 These enzymes typically 
function by adding polarity to the molecules, thereby shifting the decreasing distribution 
of the molecule to the central compartment where it can more readily be excreted into the 
urine or feces (See Figure 5).7  Understanding the mechanisms behind these enzymatic 
biotransformations is important for developing compounds with favorable dispositions. 
                              
Figure 5.  The above illustration details the metabolic fate of a drug through phase I and 
II metabolism.7,9  
Drug metabolism is divided into two types: phase I metabolism, involving mainly 
oxidation reactions, and phase II metabolism, which employs coupling mechanisms to 
conjugate a xenobiotic to a polar functional group.7  Important phase I enzymes include 
cytochrome p450 (P450), flavonoid mono oxygenase (FMO), and aldehyde oxidase 
9 
(AO).9  Uridine glucuronosyltransferase (UGT), and sulfotransferase (SULT) are two of 
the predominant enzymes responsible for phase II metabolism of drugs.  Many of these 
enzymes are found at high concentrations in the liver and intestine.  In this work, P450 
and UGT enzymes were the most relevant biotransforming enzymes. 
Cytochrome P450 is in a family of heme containing enzymes found on the 
cytosolic side of the endoplasmic reticulum of a cell.  They exist in particularly high 
concentrations in the liver.7  P450s are unique in their chemistry since they can utilize 
molecular oxygen to insert a single oxygen atom into alkyl groups.  This can add polarity 
to a molecule or a potential site for phase II reactions that may help expedite their 
removal. The overall P450 reaction is shown in Equation 7. 
(7) RH (substrate) + O2 + NADPH + H
+ → ROH + H2O + NADP
+ 
A full explanation of the catalytic cycle and mechanisms behind this remarkable enzyme 
is beyond the scope of this text, but more detailed explanation can be found in references 
7, 9.  Figure 6, however, illustrates the enzymes, cofactors, and substrates involved in the 
overall reaction.  Electrons are transferred from NADPH through various P450 reductase 
proteins to the P450 heme complex.  From here, iron and oxygen are reduced to a short 
lived Fe-O2 state, which is rapidly protonated twice, releasing water, forming the 
oxidized species, compound I or O=FeIV∙+.7,9 P450s are capable of modifying a wide 
range of compounds, with substrates typically susceptible to hydrogen abstraction.  
Common substrates include carbon atoms alpha to hetero atoms such as O, and N, or 
10 
alkyl chains, alkenes, and aromatic rings.9  Additionally, hetero atoms N and S are 
occasional substrates.9  
 
Figure 6.  In the diagram above, the electron chain transfer for cytochrome P450 is shown.  
Electrons are transferred from NADPH, through P450 reductase to the heme group in the P450 
protein where a reactive FeIVoxo intermediate inserts a single oxygen through HAT or SET 
mechanisms.7,9  
UGTs consist of four super families: UGT1, UGT2, UGT3, and UGT8. They are 
found in high concentrations in the liver and gut, but are also expressed in many other 
tissues such as kidneys, skin, brain, and various glands.  Like P450 enzymes they are 
located on the ER, but on the lumen rather than the cytosolic side.9 
Candidates for UGT glucuronidation include compounds containing nucleophilic 
centers such as phenols, alcohols, amines, and carboxylic acids.  Figure 7 depicts the 
catalytic cycle of UGT enzymes.  UDPGA is then amenable to nucleophilic attack at the 
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electrophilic C1 position of the glucuronide, with UDP as the leaving group.  Glucuronide 
conjugates from UGT result in the formation of polar β-glucuronides that can be excreted 
in the urine or feces.7,9  
α-D-Glucose-1-phosphateα-D-UDP-glucose
UDP-glucose dehydrogenase
 
Figure 7.  A depiction of the catalytic cycle of UGT enzymes is shown in the above diagram.9  
UGTs can be particularly relevant to carboxylic acid containing compounds as the 
deprotonated oxygen can readily attack UDPGA via a Sn2 reaction.  However, 
glucuronidation of carboxylic acids results in the formation of acyl glucuronides.7,9,10,11,12  
Acyl glucuronides are susceptible to trans-acylation through nucleophilic attack from a 
nucleophilic amino acid residue such as lysine.  Additionally, acyl glucuronides are able 
to undergo acyl migration and subsequent ring opening followed by glycation through a 
Schiff-base reaction with an appropriate amine containing residue (see Figure 8).  Such 
12 
reactions are problematic as they may form modified proteins, potentially triggering a 
serious immuno-biologic response.10,11,12  
13 
 
Figure 8.  A mechanism for the reactivity of acyl glucuronides is proposed in the above 
figure.  Acyl glucuronides are prone to attack from amino acids with a nucleophilic atom 
or subject to glycation via an acyl migration and subsequent ring opening.  The ring 
opening exposes an aldehyde that is liable to Schiff-base reactions with a lysine or other 
amine containing residues.  The resultant modified can potentially cause immunogenic 
responses.10  
It has been reported that from 1960 to 1999, of the 121 drugs to be removed from 
the market, 17 of them contained carboxylic acids.10  While this is certainly not a large 
percentage of compounds, many warnings have been given for over the counter NSAIDs 
(non-steroidal anti-inflammatory) such as diclofenac, indomethacin, and ibuprofen, all of 
which contain a carboxylic acid.10 -12  Many of the toxic responses caused by these drugs 
are believed to be related in part to the mechanisms mentioned above.  Predicting 
whether an acyl glucuronide metabolite will contribute to toxicity is a complicated 
subject.  Many factors such as stability of the metabolite, whether it circulates 
systemically, and how long it remains in circulation could contribute to its toxicity.10 -12 
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1.4 In vitro Tools: Cryopreserved Hepatocytes and Microsomes 
Suspended cryopreserved hepatocytes are isolated liver cells that are stored in 
liquid nitrogen.  They possess the full complement of phase I and II enzymes as well as 
all necessary cofactors for metabolism.9,13  Hepatocytes are often considered a benchmark 
assay for in vitro drug metabolism studies; however, they are not without detractions.  
Influx and efflux transporters can play a major role in how much of, or whether a drug 
can even reach metabolizing enzymes.  In suspended hepatocytes, these transporters may 
not be properly polarized, or otherwise functional, hindering accurate in vivo metabolism 
prediction.9,13,14  Additionally, hepatocytes are relatively expensive, making regular use 
somewhat prohibitive.  
Microsomes are ERs that have been fragmented and separated via centrifugation 
at 100,000 xg.  This results in formation of ER vesicles that contain many phase I and II 
enzymes, but lack many of the necessary cofactors such as NADPH and UDPGA needed 
for enzymatic activity.13,14  Microsomes are robust, versatile (provided the necessary 
cofactors are added), and relatively inexpensive.  For these reasons, microsomes are a 
mainstay for in vitro drug metabolism studies.7,14 
 Using microsomes for in vitro studies can be problematic for compounds that are 
heavily metabolized via glucuronidation, because UGTs are located on the lumen portion 
of the ER where they are not exposed to potential substrates (see Figure 9).15,16,17,18  
15 
           
Figure 9.  In the above figure both P450 and glucuronidation activity are shown; 
however, P450 is located on the cytosolic side of the ER and UGT is on the lumen side; 
substrates must first pass through the cell membrane to bind to the UGT enzymes. 
 Many strategies have been employed to release the latent potential of microsomal 
UGTs such as detergents to better predict metabolism for compounds that are substrates 
for UGT enzymes.  However, harsh methods like these often harm other relevant 
enzymes such as P450 activity.14,15  Newer methods typically employ the peptide 
antibiotic alamethicin.  Alamethicin quickly forms regular size pores in microsomes, 
while leaving P450 functional activity intact.15,18 
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In vitro studies are common in drug discovery and development.  When testing 
preclinical species, many PK parameters such as clearance can potentially be explained 
or estimated by determining the rate of metabolism in microsomes and hepatocytes.14 
These predictions can be further refined if specific enzymes responsible for a 
compound’s metabolism can be identified.  Additionally, reactive metabolites formed in 
preclinical species can be evaluated to see if they form in human microsomes or 
hepatocytes.9,14  
1.5 Principles behind LC/MS  
1.5.1 Chromatography Theory and HPLC and UPLC Applications 
 Accurately describing drug disposition requires bioanalytical techniques capable 
of separating and detecting the parent compound as well as potential metabolites.  A 
compound can have many metabolites all with varying physicochemical properties, 
requiring a robust separation method to characterize and quantitate them.  Column 
chromatography techniques such as high performance liquid chromatography (HPLC) 
and ultrahigh performance liquid chromatography (UPLC) are the single most important 
separation methodologies used in metabolism identification and PK studies.19,20 
 Liquid chromatography (LC) separates compounds by their affinity to partition 
between the stationary and mobile phases of a column.  Different compounds will vary in 
the rate at which they partition between the phases, resulting in differing elution times 
(retention time “rt”) between compounds.  The ability of a column to separate two or any 
number of compounds is dependent on its selectivity, which is a function of the differing 
partitioning coefficients of the respective compounds.  
17 
 Selectivity is affected by both the column packing material and mobile phase 
composition (which can be adjusted to achieve desired selectivity).  In drug disposition 
studies of small molecules, most columns used are reverse phase.  These columns utilize 
a hydrophobic stationary phase (silica bonded to C5, C8, or C18 alkyl chains) and a polar 
mobile phase such as water: acetonitrile mixture.  For these columns, hydrophobic 
compounds elute later than hydrophilic substances.19-21 
 A given drug may be metabolized extensively into many disparate metabolites 
with greatly varying retention factors, resulting in peaks that could elute with the solvent 
front, or conversely, some that elute late in the chromatographic run, causing significant 
broadening effects, resulting in poorer resolution with other late eluting compounds.  To 
compensate for the elution time problem of complex mixtures, a gradient profile is often 
employed.21  A gradient profile adjusts the mobile phase composition over time, and thus 
selectivity over time.  For reverse phase conditions this means an initial mobile phase 
with low organic content, which is increased in a linear or stepwise fashion.  Doing so 
changes the retention conditions of a column so that polar compounds are retained longer 
and lipophilic compounds elute sooner.  This helps keep poorly retained compounds on 
the column longer, allowing for better separation, and reduces peak broadening of 
strongly retained compounds by increasing the organic content and pushing them off the 
column before they can spread out too much due to migratory effects.  Under these 
conditions, optimal resolution of complex mixtures can be achieved.21 
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1.5.2 Principles of Mass Spectroscopy in Metabolism and PK Studies 
Mass spectroscopy (MS) has become an indispensable analytical tool in drug 
discovery, especially in regard to drug disposition characterization.22  Robust and 
sensitive, it is an invaluable method for detecting metabolites and quantifying drug levels 
in complex biological samples.  A brief explanation behind MS principles and utility in 
ADME characterization will be discussed presently. 
Mass spectroscopy coupled to HPLC or UPLC systems function by generating 
molecular ions in the gas phase from LC eluent entering the MS ionization source.  Ions 
are then transferred to the mass analyzer portion of the MS system where they can be 
selected and manipulated according to their mass to charge ratio (m/z) and sent to the 
detector where the molecular weights and intensities of ions entering the detector can be 
deduced.22  
Many types of MS systems are available, the suitability of which is dependent 
upon the application.  In this work two types of mass spectrometers were employed: a 
Sciex API-4000 Qtrap and Waters Xevo G2 QToF.  The API-4000 Qtrap is a type of 
triple quadrupole (QQQ) mass spectrometer while the Waters instrument is a single 
quadrupole coupled to time of flight mass analyzer (QToF).  Both systems provide 
unique and complementary strengths that offset their respective limitations.  
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The API-4000 utilizes an electrospray ionization (ESI) source to generate 
molecular ions.  ESI generates molecular ions by first aerosolizing the LC flow through 
capillary forces, then charging the molecules through application of a high electric field.  
Charged molecules in the aerosolized droplets are desolvated through continued exposure 
to ESI gases and heat, decreasing the droplet size over time.  As the droplet size 
continues to shrink, ion repulsion increases until columbic repulsion results in ion 
ejection from the droplets into the gas phase.  Figure 10 provides an illustration of this 
process.20,21  
 
Figure 10.  A schematic of the electrospray ionization process is shown above. 
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Ionization takes place in either positive or negative mode with generated ions 
being drawn to the mass analyzer portion via a combination of electric field and vacuum 
forces.  The many disparate ions entering the MS migrate to the Q1 quadrupole where 
they are exposed to a complex electromagnetic field, causing ions to adopt an oscillatory 
procession down the axis of the quadrupole; only ions with appropriate m/z ratios will 
maintain an appropriate trajectory to reach the second quadrupole, Q2.  Collison gas N2 is 
injected into Q2 and ions entering will collide with the gas, causing the molecules to 
fragment into daughter ions, which can be selected for in Q3.  As in Q1, only ions with 
appropriate m/z ratios will reach the detector where the intensity (counts per second 
[cps]) will be recorded (see Figure 11).21  
 
Figure 11.  A schematic for multi reaction monitoring (MRM) using a QQQ mass spectrometer. 
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Ion fragmentation is an important aspect of triple quadrupole systems’ selectivity 
since molecular ions fragment in a unique and predictable manner.  Figure 12 illustrates a 
hypothetical fragmentation difference between two isobaric ions, an acetaminophen-
hydrogen-adduct ion and 3-(2-hydroxyacetal)-benzenaminium ion.  Both ions have the 
same amu (atomic mass unit), but acetaminophen fragments at the relatively weak amide 
bond, where the benzenaminium likely would not.  This uniqueness in fragmentation 
allows ions with similar amu to be distinguished and monitored for in a highly selective 
manner.  Figure 11 illustrates this process; as can be seen, many species of ions may be 
present in Q0; however, specific masses can be selected in Q1 (red ion) and fragmented to 
daughter ions, which can be selected in Q3 (green ion), then detected.  This method of 
detection is referred to as multi reaction monitoring (MRM).  Selection of a parent and its 
daughter ion is referred to as a transition; many transitions can be scanned for 
simultaneously when using MRM mode.  
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Figure 12.  A hypothetical fragmentation pattern of two isobaric ions. 
 
QQQ quadrupole systems excel in quantitation applications when using MRM 
scanning conditions.  Typically, standard curves containing the compound(s) of interest 
are used to measure the analyte concentrations in samples.  A peak response measured in 
cps is recorded for each known standard, and linear regression is used to generate a 
response curve based on the intensity of each standard response.  This curve is then used 
to quantify unknown samples through measuring the magnitude of their response relative 
to the standard curve.  Since biological matrices contain myriad substances, some of 
which may interfere with the ionization process, it is important to prepare standard curves 
in a similar matrix to those of the samples, to ensure similar ionization conditions.  
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Moreover, use of an internal standard (IS) is often employed (one with a similar structure 
and retention time is desirable) to help account for ion suppression as well as account for 
extraction efficiency during the sample preparation process.  A well-chosen IS will have 
similar extraction ratios to the analyte of interest and will be subject to similar ionization 
suppression/enhancement effects.  MRM is very sensitive, selective, and often capable of 
detecting compounds at very low concentrations. 
 Aside from quantitation, QQQ systems can be used for metabolite detection 
purposes.  Since drug biotransformations modify a compound’s molecular weight 
according to the specific type of biotransformation, MRM transitions incorporating these 
changes to parent and daughter ions can be used to monitor for specific metabolites in a 
sample.20  Figure 13 gives a generic illustration of the process: here the parent unmodified 
ion is represented as a connected rectangle and oval, which fragments into rectangle and 
oval ions.  Directly below the parent ion are metabolites which have undergone 
enzymatic modification indicated by the addition of an X and Y.  These too will likely 
fragment similarly to that of the parent ion; however, the daughter ions will have amu 
values differing by the mass of X and Y respectively.  By adding transitions that 
incorporate the mass changes caused by X and Y modifications, these metabolites can be 
detected and the location of biotransformation can be narrowed.  
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Figure 13.  Use of MRM scanning mode with QQQ systems for metabolite identification. 
 QToF spectrometers function similarly to QQQ systems from the ionization 
source to the quadrupole; however, the method of selection differs significantly.  As the 
name implies, QToF systems separate ions based on their time of flight. When analyzing 
for small molecules, ions typically have a single charge, meaning all ions have the same 
kinetic energy, but different velocities that depend on the mass of the ion (i.e. heavier 
ions will travel more slowly than lighter ions).  Rather than filtering ions through 
electromagnetic fields and fragmentation, ion amu are deduced simply by the time it 
takes an ion to traverse the known distance to the detector.21  This difference in selection 
imparts capabilities not present in QQQ systems, and makes QToF platforms ideally 
suited for metabolite identification studies.  
 Two of these attributes are high mass resolving power and accurate mass 
measurements.  Mass resolution is the ability of a mass spectrometer to distinguish ions 
of differing molecular weight and is defined by an ion’s MW divided by change in mass 
at ½ peak height (Equation 8).23,24 
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(8) 𝑅𝑒𝑠𝑜𝑙𝑣𝑖𝑛𝑔 𝑃𝑜𝑤𝑒𝑟 = 𝑚𝑎𝑠𝑠/∆𝑚𝑎𝑠𝑠 
 Mass accuracy is the ability of the mass spectrometer to measure an ion’s true 
mass and is determined by measuring the mass error (the absolute difference between 
measured ion mass and actual mass).  Accuracy is typically measured in parts per million 
(ppm) defined by Equation 9.23,24 
(9) 𝑚𝑎𝑠𝑠 𝑒𝑟𝑟𝑜𝑟 𝑖𝑛 𝑝𝑝𝑚 =
𝑚𝑎𝑠𝑠 𝑒𝑟𝑟𝑜𝑟
𝑎𝑐𝑐𝑢𝑟𝑎𝑡𝑒 𝑚𝑎𝑠𝑠
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 Accurate mass spectroscopy allows for a more certain identification of unknown 
metabolites, even in complex matrices such as bile and plasma.24  An endogenous 
substance may ionize and have a very similar mass to a metabolite, but if the mass error 
is above the threshold of that mass spectrometer, it is not a metabolite.    
1.6 Goal and Objectives 
 Telmisartan is an excellent candidate to assess the effect on dispositional changes 
caused by substitution of carboxylic acid with a tetrazolone.  Telmisartan disposition 
across species is well documented and very similar across species.25,26,27  In all tested 
preclinical species, telmisartan is predominately glucuronidated to the acyl glucuronide 
metabolite, then eliminated via biliary excretion into feces.  All metabolism occurs 
through the UGT1A family in humans and preclinical species, with no P450 or other 
phase I or phase II reactions observed for in vivo or in vitro systems.25 
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 Since telmisartan is cleared though metabolism of the carboxylic acid moiety, 
replacement of it with a tetrazolone may have a significant effect on the PK profile and 
metabolism.  The tetrazolone analog R941000 could be excreted unchanged, 
glucuronidated, eliminated at a different rate, or undergo other biotransformations such as 
P450 oxidation.  
 Finally, SD rats were used as a model preclinical species since they are readily 
available and commonly used as an initial preclinical test species.  PK parameters such as 
Cl, V, half-life, AUC (exposure), and Cmax (highest plasma concentration) were 
determined using non compartmental analysis (NCA).  Human in vitro metabolism was 
assessed using human cryopreserved suspended hepatocytes and liver and intestinal 
microsomes and compared to rat metabolism in the same in vitro platforms. 
2.0 Experimental 
2.1 Chemicals & Biological Materials 
 Telmisartan was purchased from TCI-America (Portland, OR), Bexarotene from 
LC Laboratories (Woburn, MA), Indomethacin from Alfa Aesar (Ward Hill, MA). 
Reduced NADPH salt, β-Glucuronidase, MgCl2, UDPGA, DMSO, midazolam, 
propranolol, warfarin, and diclofenac were obtained from Sigma Aldrich (St. Louis, MO).  
Alamethicin was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). 
R941000, R941006, and R941007 (telmisartan, bexarotene and indomethacin tetrazolone 
analogs respectively) were synthesized and purified by Matthew Duncton at Rigel 
Pharmaceuticals Inc. (South San Francisco, CA).  HPLC grade water and acetonitrile 
were purchased from Fisher Scientific (San José, CA).  
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Human and rat liver and intestinal microsomes were purchased from BD Genquest (San 
José, CA) and XenoTech (Lenexa, KS).  Human and rat hepatocytes were obtained from 
XenoTech (Lenexa, KS).  Rat plasma was purchased from Bioreclimation (Baltimore, 
MD). 
2.2 Formulation Preparation 
 Both telmisartan and R941000 sodium salt formulations were prepared by 
dissolving the weighed material in 0.5 N NaOH and bringing up to appropriate volume in 
saline.  The pH was then lowered to approximately 9.5 with 0.5 N HCl according to 
protocols detailed by Wienen (2007) & HAO (2012).  Formulations were then dosed 
intravenously (IV) or orally (PO).25-27  
2.3 Pharmacokinetic Studies 
 Sprague Dawley rats were dosed with either R941000 or telmisartan between 0.7-
4 mg/kg.  Formulations were administered either intravenously or orally, and blood was 
taken through the jugular vein at the following time points: 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 
24 h, centrifuged, and stored at -80 0C (as plasma samples) until ready to analyze.  
Samples were prepared by thawing at room temperature, and then adding 50 µl of plasma 
samples to 200 µl of IS containing acetonitrile to precipitate protein and extracting 
R941000 or telmisartan.  A ten point standard curve ranging from 2-2000 ng/ml and 
quality controls (QCs) were prepared by adding 10 µl of appropriate concentration 
DMSO stock to 50 µl blank rat plasma, and then precipitating with 200 µl of IS 
containing acetonitrile, like the animal samples.  Samples, standards, and quality controls 
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were then vortexed and centrifuged.  Supernatant were then transferred to a 96 (1.2 ml) 
deep well plate and analyzed via a LC/MS API-4000 Q-trap (AB Sciex, Redwood City, 
CA) coupled with a Shimadzu 10Avp HPLC and SIL-5000 auto injector (Shimadzu, 
Pleasanton, CA).  
 In brief, samples were separated on an Essensil AF-C18 3µ 50x2.1 mm column 
using 0.05% formic acid in water (mobile phase A) and acetonitrile (mobile phase B) 
with a 0.4 ml/min flow rate.  Initial column conditions consisted of 5% B for 0.5 min, 
then a linear increase from 5% B to 95% B over 2.5 min, followed by a 0.7 min wash 
phase (95% B), and then 0.7 min re-equilibration (5% B).  Samples were ionized using an 
electrospray ionization (ESI) source on positive ion mode, with an ionization energy of 
5500 V at 550 0C, and monitored using MRM mode.  Telmisartan parent/daughter 
transitions were 515.2/497.2 amu with a 100 ms dwell time, 156 V declustering potential 
(DP), 45 V collision energy (CE) and 6 V exit potential (CXP). R941000 transitions are 
555.2/484.2 amu, 100 ms dwell time, 71 V DP, 33 V CE and 6 V CXP.   
 The NCA pharmacokinetic profile of R941000 and telmisartan was assessed using 
Phoenix-WinNonlin software (Certara, Princeton, NJ).  
2.4 Elimination Route Studies 
 Jugular vein cannulated SD rats were orally dosed with 3.5 mg/kg R941000 or 
telmisartan (n=3).  Urine samples were collected at 0-6 h and 6-24 h, and feces were 
collected over a 24 h time period.  Total volume and mass of urine and feces were 
recorded.  
29 
 Urine samples were prepared and analyzed in exactly the same manner as plasma 
samples.  Once the concentration in urine was determined, the total amount of drug in 
urine and percentage of dose could be calculated by multiplying the concentration by 
total volume (amount of compound) and then dividing by total dose received and 
multiplied by 100 for a percentage of dose excreted.  Feces were first diluted in 10 ml of 
DMSO:water (50:50) and homogenized using a Biolabs (Manassa, VA) probe sonicator.  
Feces homogenate was then processed and analyzed in the same fashion as plasma and 
urine.  The total amount of compound in feces was determined by estimating the 
DMSO:water dilution factor and multiplying it by the concentration of compound and 
total mass of feces collected.  Percentage of dose in feces was determined by dividing the 
total amount found over total dose received multiplied by 100. 
2.5 Hepatic Extraction Studies 
 Jugular and portal vein cannulated SD rats were dosed with 3-4 mg/kg R941000 
or telmisartan and samples were collected at 0.5, 1, 2, 4, 6 h and stored at -80 0C.  Plasma 
samples were then prepared and analyzed as previously discussed.  Hepatic extraction 
was determined by Equation 10:   
(10) HE = (1 −
AUCJV
AUCPV
) ∗ 100  
Where HE is hepatic extraction, AUCJV is area under the curve for jugular vein, and 
AUCPV is area under the curve for portal vein.  
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2.6 Rat Bile Metabolite Identification Studies 
 Bile duct cannulated SD rats were dosed with 3-4 mg/kg of R941000 or 
telmisartan IV or PO and bile was collected from -1-0 h (pre-dose), 0-2 h, 2-4 h, and 4-6 
h intervals and stored at -80 0C until ready to use.  Samples were thawed, and aliquots 
from each time point were diluted 5-10 x fold in 0.1% formic acid containing water, 
vortexed and centrifuged to remove any non-dissolved bile components, and analyzed on 
a Waters Xevo G2 QToF, coupled to an Acuity UPLC system (Milford, MA).    
 Samples were then separated using a Phenomenex Kinetex C-18 100x2.1mm, 
1.7µm UPLC column with an acetonitrile gradient (0.1% formic acid in water [A] and 
acetonitrile [B]) with a flow rate of 0.4 ml/min maintained at 35 0C.  The column was 
equilibrated for 3 min at 15% B, then a linear increase from 15% to 60% B over 7.5 min, 
followed by a sharp increase to 95% B and a 3 min wash phase; finally, the column was 
re-equilibrated for 3 min at 5% B.  Parent and metabolites were detected with the Acuity 
UPLC PDA detector and mass spectroscopy detector in survey ion mode (positive ion 
mode with ESI) with a mass range of 50-1000 amu and 200 msec scan time.  The 
collision energy was set to a low (10 V) and high (30 V) collision energy and ramped 
from 20-60 V to optimize fragmentation of parent and daughter ions.  Alternatively, the 
API-4000 Q-trap was used for metabolism identification, due to its greater sensitivity.  
Conditions used were similar to those used for plasma samples with the exception of a 
longer column (Phenomenex Luna C18, 5uM 150x3 mm column) and longer gradient 
method (20 min) with a 0.5 ml/min flow rate and 2 min equilibrium phase (5% B), 13 
min gradient phase (5% to 95% B), followed by a 2 min wash phase (95% B) then 3 min 
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re-equilibrium phase (5% B).  MRM transitions were set for 555.3/484.2 (R941000), 
731.3/555.3 (R94000-glucuronide), 571.2/500.2 (oxidated-R941000), 515.2/497.2 
(telmisartan), and 691.3/515.2 (telmisartan-glucuronide). 
2.6.1 β-Glucuronidase 
E. Coli β-glucuronidase was used to cleave O-glucuronides in bile samples by 
incubating 1,000 units of enzyme in bile samples buffered to pH 4 in sodium acetate 
buffer for four hours at 37 0C.  Bile samples were then diluted 10x in 0.1 % formic acid 
containing water, vortexed, centrifuged, and analyzed on an API-4000 Qtrap using MRM 
parameters described previously. 
2.7 Microsomal Stability Studies 
 Human and rat liver microsomes were thawed and diluted to a concentration of 
1mg/ml microsomal protein in 100 mM phosphate buffer, pH 7.4, and aliquoted into 1.5 
ml plastic micro-centrifuge tubes. A 1 mM DMSO stock containing test article (TA) was 
added to centrifuge tubes for a final TA concentration of 1 µM.  The TA/microsomal 
suspension was aliquoted in a 96 deep well plate (in duplicate) and pre-incubated at 37 0C 
for 5 min.  Following pre-incubation, a 40 mM stock of NADPH was added to the pre-
incubated microsomes for a final concentration of 1 mM NADPH to initiate the reaction.  
Immediately following the NADPH addition, an aliquot from the TA/microsome solution 
was taken and quenched in acetonitrile (at 0 0C) containing internal standard (IS) for an 
initial time zero.  Additional aliquots were taken at 5, 15, 30, and 45 min.  Following 
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quenching, samples were diluted 3 fold in 0.1% formic acid in water, then vortexed, 
centrifuged, and analyzed via LCMS. 
 The relative stability of the TA was determined by tracking the disappearance of 
the TA over time by a linear plot of TA/IS peak area ratio.  From the linear plot, the 
elimination constant, k, was estimated and the half-life of the TA was determined through 
Equation 11:  
(11) 𝑡1
2⁄ =−
ln (2)
𝑘
 
2.7.1 UDPGA and Alamethicin Supplemented Human and Rat Liver and Intestinal 
Microsomes 
 The protocol for UDPGA supplemented and alamethicin treated microsomes was 
identical to the microsomal protocol with the exception of the following conditions:  
Microsomes were diluted to a final concentration of 1 mg/ml in phosphate buffer (pH 
7.4) containing 1 mM MgCl2 with the addition of alamethicin (at 50µg per mg of 
microsomal protein) and stored on ice for 15 min.  Moreover, the reaction was initiated 
with the addition of UDPGA and NADPH (final concentration 5 mM and 1 mM 
respectively).  Samples were quenched similarly to the previous microsome protocol at 0, 
0.5, 1, and 2 h and prepared for analysis in the exact same manner as previously 
discussed. Samples were analyzed on the API-4000 Q-trap and monitored for TA and 
metabolites of TA.  
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2.8 Metabolite Identification through Cryopreserved Human and Rat Hepatocytes 
Human and rat cryopreserved hepatocytes (HCH and RCH) were prepared 
following the protocol delineated by XenoTech for thawing cryopreserved hepatocytes 
(kits 2000, 2100, 2600).28  Briefly, the hepatocytes were thawed in a water shaker bath at 
37 0C for approximately 80 seconds and placed in solution A (Dulbecco’s modified 
eagles medium [DMEM] and isotonic percoll), and 4.5 ml of tube B (DMEM) were 
added to hepatocyte suspension.  The suspension was then centrifuged at 100 xg for 5 
min at 37 0C, and the resulting supernatant was aspirated off.  The remaining solution of 
tube B was added to pelleted hepatocytes, re-suspended, and centrifuged again at 60 xg 
for 3 min.  Supernatant was aspirated off and the pelleted hepatocytes were gently re-
suspended with a small volume of Krebs-Henseleit buffer (KHB). An aliquot of 
hepatocytes was stained with trypan-blue dye and then placed on a hemacytometer to 
determine cell viability.  Once the number of viable hepatocytes were estimated, the 
remaining hepatocyte solution was diluted approximately 1.75x106 cells/ml.  Re-
suspended hepatocytes were then added into 24 well polystyrene plates followed by a 
0.75 x dilution with incubation media (pre-incubated to 37 0C) containing R941000, 
telmisartan, or blank (final substrate concentration 10µM).  Cells were then incubated at 
37 0C under 5% CO2 atmosphere.  Aliquots were then taken and quenched at 0, 2, and 4 h 
by adding to ice cold acetonitrile (1 x dilution).  Four volumes of water containing 0.25% 
formic acid were then added to the quenched samples.  HCH and RCH samples were then 
vortexed, centrifuged, and processed using the Waters Xevo G2 QToF and Acuity 
UPLC/MS. 
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2.9 Plasma Protein Binding 
The percentage of R941000 and telmisartan bound to plasma proteins was 
determined using a Life Technologies Single-Use RED (rapid equilibration dialysis) 
device (Thermo Scientific, Research Triangle Park, NC).  The assay was prepared by 
adding 500 µl of PBS (phosphate buffer saline), 1x solution to buffer side of plate, and 
300 µl of plasma containing 2 µM TA.  Samples were then mixed at approximately 800 
rpm for four hours.  Following the equilibration period, 50 µl plasma and buffer were 
removed from their respective wells and added to a 1.2 ml 96 deep well plate; 50 µl of 
blank buffer was then added to the plasma portion and 50 µl of blank plasma was added 
to buffer portion to normalize the samples; next, 300 µl of acetonitrile containing IS was 
added to each sample well, vortexed, and centrifuged.  Supernatant was then transferred 
to a 96 deep well plate and analyzed via LC/MS in the same manner as the plasma PK 
samples. 
3.0 Results 
Results are divided into two sections: the first deals with pharmacokinetic and 
elimination behavior of R941000 and telmisartan through IV, PO, hepatic extraction, and 
elimination pathway studies; the second section looks at the metabolism of the two 
compounds in cryopreserved hepatocytes, and microsomes as well as in vivo metabolic 
profiling through analysis of rat bile from SD rats dosed with compound. 
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3.1.0 Pharmacokinetic Studies 
Jugular vein (JV) cannulated SD rats were dosed IV with 0.70 and 0.79 mg/kg of 
R941000 and telmisartan, respectively, with three rats per study (n=3).  Plasma samples 
were analyzed at the mentioned collection times from the PK experimental section for IV 
and PO studies.  Figures 14 and 15 depict the IV PK profile of R941000 and telmisartan, 
respectively, with the upper and lower graphs representing the concentration over time 
and the linear plot concentration over time, respectively. 
 
 
Figure 14.  The top graph shows the PK profile of R941000 dosed via an IV bolus and the 
resultant concentration over a 24 h period.  The lower graph depicts the linear plot of the same 
data. 
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Figure 15.  The top graph shows the PK profile of telmisartan dosed via an IV bolus and the 
resultant concentration over a 24 h period.  The lower graph depicts the linear plot of the same 
data. 
 From NCA analysis, the PK parameters for both R941000 and telmisartan were 
determined, and are given in Table 1. 
Table 1.  IV PK parameters of R941000 and telmisartan 
 IV IV 
R941000 Telmisartan 
0.7 mg/kg 0.79 mg/kg 
Variable Mean SD± Mean SD± 
AUC_inf (ng*h/L) 2610 326 1850 258 
AUC_last (ng*h/L) 2490 249 1830 245 
Cl_pred (ng*ml/min) 4.51 0.691 7.23 1.09 
t1/2 (h) 5.37 1.58 3.64 0.837 
Vss (L/kg) 1.67 0.242 1.59 0.14 
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 Overall exposure for R941000 (2,610 ng/ml ± 326) is greater than telmisartan 
exposure (1850 ± 258), though it was given at an 11% lower dose.  When the R941000 
and telmisartan doses are normalized, the AUC of R941000 exceeds telmisartan by 
nearly 1.6 fold while Cl was reduced by a factor of 1.5. 
 SD rats were orally dosed with 3.5 mg/kg and 3.95 mg/kg of R941000 or 
telmisartan, respectively.  Their plasma concentrations over 24 h were recorded and the 
resultant PK profiles can be seen in Figure 16 (R941000) and Figure 17 (telmisartan) 
with the oral PK parameters given in Table 2. 
 
 
 
Figure 16.  PK profile of PO dosed R941000. 
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Figure 17.  PK profile of PO dosed 
telmisartan. 
 
 
Table 2.  The PO PK parameters for R941000 and telmisartan. 
PO PO 
R941000 Telmisartan 
3.5 mg/kg 3.95 mg/kg 
Variable Mean SD± Mean SD± 
AUC_inf (ng*h/L) 8440 1160 5480 1850 
AUC_last (ng*h/L) 8420 1660 5460 1860 
Cl_F_pred 
(ng*ml/min) 
7.08 1.29 12.9 3.85 
t1/2 (h) 2.65 0.320 2.55 0.856 
Cmax (ng) 1330 515 506 158 
%F 64.70% 59.20% 
 As can be seen from the PK profiles, R941000 and telmisartan differ when 
administered through a PO route.  R941000 has a clear Tmax at 2 hours, but telmisartan 
has a plateaued profile with a large standard deviation and potential Cmax values between 
4-8 hours, depending on the animal.  In addition to the relatively rapid absorption and 
definitive Tmax, R941000 has a much greater Cmax.  From Table 2, it can be seen R941000 
Cmax is over 2.5 fold greater than telmisartan and increases to 3 fold when the doses are 
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normalized.  Moreover, the overall exposure is 1.7 x greater than telmisartan, yet the half-
lives are near equivalent.   
 A possible explanation of the prolonged telmisartan Tmax may be due to its ability 
to undergo enterohepatic recirculation (conversion of the biliary excreted metabolite back 
to parent and reabsorption in the intestinal lumen).25,26  Since telmisartan undergoes 
significant glucuronidation and biliary elimination, the O-acyl glucuronide metabolite in 
bile may serve as a telmisartan reservoir when endogenous gut β-glucuronidase 
hydrolyses the metabolite back to telmisartan.25  
Samples were reanalyzed with MRM transitions monitoring for telmisartan-O-
acyl glucuronide to see if enterohepatic recirculation may play a role in the observed 
telmisartan oral PK profile.  Orally dosed samples showed a minor peak (2.47 min) eluted 
just prior to the major, parent peak (2.67 min) when observing the telmisartan MRM 
transition (see Figure 18).  This observation was consistent with in source fragmentation 
of a glucuronide.  In source fragmentation refers to ions fragmenting during the 
ionization process.  Molecules with relatively weak bonds can undergo in source 
fragmentation, and in the case of an acyl glucuronide would be converted back to the 
parent ion.  Since an O-acyl-glucuronide of telmisartan is more polar than its unmodified 
parent, it would elute first, showing two peaks when monitoring for telmisartan.  When 
monitoring for the glucuronide metabolite a noticeable peak was observed at 2.47 min, 
the same as the in source fragmentation peak detected on the telmisartan MRM channel, 
providing evidence of an acyl glucuronide metabolite (Figure 18). 
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Figure 18.  Chromatograms of telmisartan (top) and telmisartan-O-acyl glucuronide (bottom) 
MRM channels for orally administered SD rats at 0.5 h. 
3.1.1 Hepatic Extraction 
 Telmisartan is glucuronidated in the GI track; however, the UGT1A family of 
enzymes responsible for glucuronidation becomes saturated with higher doses of 
telmisartan (greater than 1 mg/kg), and much of the glucuronidation falls to UGT1A 
enzymes in the liver.25  Since the liver plays a prominent role in telmisartan metabolism, 
it was desirable to assess the magnitude of R941000 metabolism in liver through hepatic 
extraction studies.  Determining hepatic extraction is performed by measuring drug 
concentration in both pre and post hepatic blood/plasma.  This is often accomplished via 
jugular and portal vein cannulated rats. Since blood in the portal vein leads directly from 
the gut to the liver, measuring drug concentration in the portal vein is suitable for pre-
hepatic concentration measurements.  
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Though somewhat distant from blood flow leaving the liver, drug concentration in the 
jugular vein is measured to determine the post hepatic concentration.  In this study SD 
rats were dosed orally with either R941000 or telmisartan at approximately 3.5 mg/kg.  
Plasma samples were collected from both the jugular and portal veins from 0.5 to 6 h, 
with concentrations of compound recorded in Figure 19.  In addition to the concentration 
profiles, Figure 19 contains the AUCs of both compounds as well as hepatic extraction 
ratios. 
 
Figure 19.  Hepatic extraction ratios of R941000 (right) and telmisartan (left) are shown in the 
plot of compound concentration over time, and the percentage metabolized by the liver are 
shown in the tables listed below each graph.  Both R941000 and telmisartan were dosed orally 
in SD rats (n=3) with concentration being measured over 6 h. 
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From the graphs, it can be seen for R941000 that the portal vein is initially higher 
in concentration than the jugular vein during the absorption phase (this is common for an 
orally dosed compound since all the drug is being absorbed from the gut and carried to 
the liver through the portal vein).  During the terminal phase, however, there is little 
difference between the jugular and portal vein, suggesting minimal first pass effect in the 
liver.  Indeed, only a 4% hepatic extraction was observed for R941000.  Additionally, the 
PK profile for the HE study looked similar to the PO studies with rapid absorption and a 
clear Cmax.  Telmisartan possessed a later and lesser Cmax than R941000, and had a HE of 
nearly 28% indicating a greater first pass effect from the liver.  
3.1.2 Elimination Studies 
Next, changes in elimination routes were assessed in SD rats, through collection 
of urine and feces over a 24 h period.  Typically, mass balance studies using radiolabeled 
compounds to definitively determine when and how drug has left a body are employed.  
Unfortunately, radiolabeled compounds are very expensive and were not an option; 
however, a qualitative study would still provide valuable insight since any significant 
quantity found in urine would indicate a change in clearance route of the tetrazolone 
analog.  
SD rats were dosed with R941000 or telmisartan at approximately 3.5 mg/kg.  
Urine and feces were collected over a 24 h period and the amounts in the respective 
matrices were determined as described in the experimental section.  Results can be found 
in Table 3. 
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Table 3.  Excretion amounts of R941000 and Telmisartan 
R941000 Telmisartan 
Urine < 1% Urine < 1% 
Feces approx. 40% Feces approx. 50% 
 
Approximately half of the oral dose was found in feces for both telmisartan and 
R941000 with only trace amounts detected in urine.  Unfortunately, the samples were 
dosed orally, and 50% most likely correlates with the fraction of compound not absorbed 
by the gut (see Table 2, %F).  Literature searches revealed most mass balance studies for 
telmisartan were conducted over 96 h, with over 90% of the compound excreted in feces 
the first 48 h.25 While non-radiolabeled recovery studies are qualitative in nature, the low 
overall recovery may indicate much of the compound was still in the body after 24 h, 
metabolized, or that excreted compound was poorly extracted from feces samples.  The 
lack of parent compound or metabolites found in urine over 24 h for both compounds 
suggests they both undergo biliary excretion.    
3.2.0 Rat In vivo Metabolism:  Searching for Metabolites in Bile 
Compounds undergoing hepatic metabolism (such as telmisartan) can be 
transported and concentrated in the bile, where they can be concentrated and easier to 
detect.25 Bile duct cannulated rats were orally or intravenously dosed with 3.5-4 mg/kg 
R941000 or telmisartan, and bile was collected at 4 time points, -1-0 h (pre-dose), 0-2 h, 
2-4 h, and 4-6 h.  Samples were then prepared as described in the experimental section, 
and then analyzed on either a Waters G2 Xevo QToF, or Applied Biosystmems API-4000 
Qtrap.  
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A neat solution of 1 µM R941000 was prepared and run on the Waters UPLC-QToF 
platform, to determine the retention time of the molecule, the suitability of the gradient, 
and to elucidate the fragmentation pattern of R941000.  An extracted ion 
chromatogram (XIC) shows a peak at 6.71 min (Figure 20, top). Analysis of the mass 
spectra at 6.71 min revealed numerous ions including a major ion with 555.260 amu, 
matching the hydrogen adduct molecular weight of R941000 with a mass error of 3.40 
ppm.  In addition, major fragments of R941000 were observed at 305.177, 251.094, 
and 208.076 amu (Figure 20, bottom).  Figure 20 shows the likely portions of R941000 
fragment ions 305.177 and 208.076 amu represent (generated using Excalibur 
software).
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Figure 20.  (Top) XIC chromatogram of 1µM R941000 in neat solution of 50:50 CH3CN:H2O. 
(Bottom) Mass spectra showing fragmentation pattern of R941000 from peak at 6.71 min. 
Following the neat solution of R941000, the pre-dose through 6 h bile samples 
were analyzed using the same gradient and mass spectra conditions.  XICs of bile 
samples for parent (R941000 hydrogen adduct) at 555.262 amu for all time points were 
performed and can be seen in Figures 21a-d.  Distinct peaks were observed in the 2, 4 and 
6 h samples, but absent in the pre dose sample.  
 
Figure 21.  XICs of R941000 hydrogen adduct at 555.262 amu are shown for the pre-dose, 2, 4, 
and 6 h a-d samples, respectively. 
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 In bile samples, the rt of R941000 shifted from 6.71 min in the neat solution to 
6.91 min in the bile matrix solution; this is not uncommon for a complex matrix such as 
bile.  Moreover, for the 2 through 6 h, multiple peaks of the parent 555.262 amu were 
observed, with increasing peak intensity of the earlier eluting species at the 4 and 6 h 
collection times.  As previously discussed, observation of compounds with earlier 
retention times yet same mass can be indicative of in source fragmentation of a 
metabolite back to the parent structure. 
 An XIC of 731.293 amu (corresponding to a R941000-glucuronide [H+] amu) 
resulted in the disappearance of the parent peak at 6.91 min, but remainder of earlier 
eluting peaks observed for XICs of 555.262 (Figure 22).  For the 2 h bile sample (Figure 
22 a) two distinctive peaks are visible at 6.32 and 5.88 min with a third peak appearing at 
about 5.4 min.  XICs of the 4 and 6 h samples (Figure 22) revealed similar 
chromatograms.  
 Analysis of the mass spectra fragmentation patterns of the XIC peak at 6.3 min 
yielded a major ion with a MW of 731.291 amu with over a million cps.  Additionally, 
the R941000 ion, 555.262 amu, was observed along with its characteristic fragments, 
305.177 and 251.094 amu ions (Figure 23).  Similar observations were made for the 5.8 
and 5.4 min XIC peaks.  Mass spectra of the 5.8 min peak yielded fragmentation patterns 
with the parent compound ion and characteristic fragmentation ion of 305.177 amu.  The 
mass spectra of the 5.4 min peak had a mass error of 16 ppm from the glucuronide 
metabolite amu and therefore is not a metabolite. 
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Figure 22.  XICs of 731.29 amu from 2, 4, and 6 h bile samples are shown in top, middle, and 
bottom, respectively. 
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Figure 23.  The above chromatograms show the mass spectra fragmentation patterns for the XIC 
(731.291 amu) chromatogram peaks at 6.3, 5.8, and 5.4 min (top, middle, and bottom, 
respectively) for the 4 h time point as well as their respective mass errors. 
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Analyzing the chemical configuration of R941000, two glucuronidation sites are 
apparent on the tetrazolone.  The tetrazolone can tautomerize and exist in the enol 
or keto form, revealing either a nucleophilic oxygen (at the number 5 carbon on the 
tetrazolone ring) or nitrogen (number 4 nitrogen on the tetrazolone ring), depending 
on the tautomer.  Either the oxygen or nitrogen can attack the electrophilic carbon 
on position one of the glucuronide, displacing UDP in an SN2 type reaction, 
forming either an O- or N-glucuronide (Figure 24). 
 
Figure 24.  Tetrazolones can tautomerize between the keto and enol form, revealing two 
nucleophilic atoms capable of displacing UDP in an Sn2 attack forming an O- or N-
glucuronide. 
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 β-glucuronidase was next employed to test if the observed glucuronides 
corresponded to O/N-glucuronides. N-glucuronides are stable to β-glucuronidase while O-
glucuronides are readily cleaved.29,30  The API-4000 was chosen for analysis of the samples, 
due to its excellent sensitivity.  The parent eluted at 10.81 min, preceded by a peak at 10.13 
min, a minor peak at 9.59 min, and a second major peak at 9.29 min.  The results of these 
experiments are shown in Figure 25, where the XICs of the R941000-glucuronide 
metabolites are shown for the 2-4 h bile time point without (top) and with (bottom) 
incubation in β glucuronidase at 37 0C.  As can be seen, incubation of the rat bile with β-
glucuronidase resulted in the disappearance of the 9.29 min peak, while the 10.81 min peak 
and minor peak remained.  Therefore, the peak at 9.29 is likely to be an O-glucuronide, and 
the peak at 10.13 min an N-glucuronide. 
 
Figure 25.  Top, XIC of 731.29 amu of rat bile 2-4 h after being dosed with R941000; bottom, XIC 
of 731.29 amu after 1 h incubation with β-glucuronidase at 37 0C. 
 
51 
 After the potential identification of R941000 O- and N-glucuronides, a search for 
other less obvious metabolites began.  The Waters QToF system was utilized for this 
purpose, due to its accurate mass and UV absorption capabilities.  An initial check of the 
UV absorption chromatograms for all bile samples including the pre-dose was done at a 
300 nm wavelength.  A comparison of the pre-dose with later time points showed 
significant absorption at the glucuronide metabolite retention times, some absorption at 
the parent rt (6.91 min), and some additional peaks next to the parent (Figure 26 bottom).  
A wavelength of 300 nm was chosen to minimize non-specific matrix absorption, yet 
maintain absorption of parent and metabolites. 
 
Figure 26.  Top, UV of bile at pre-dose. Bottom, UV of bile at 2-4 h. 
 
 Next, XICs of common biotransformations were performed on all bile collection 
time points to determine if there were any other metabolites in the bile that either did not 
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absorb, or co-eluted with parent or other glucuronides.  XICs of R941000 plus common 
biotransformation were searched for.  These included oxidized metabolites and various 
phase II modifications, plus oxidation.  However, the only other metabolites found were 
multiple singly oxidized species eluting at approximately 7.0, 6.8, and 6.5 min (Figure 27 
top).  Mass fragmentation patterns gave ions with parent +15.995 (addition of oxygen 
hereafter referred to as +16) for the above stated peaks (only shown for 6.8 min peak for 
2-4 h bile sample [Figure 27 bottom]).  As can be seen, there is a 208 amu fragment 
visible in Figure 27, indicative of the biphenyl portion of R941000 (Figure 28).  In 
addition, there is a prominent 321 amu ion in place of the regularly observed 305 amu 
benzimidazole fragment of the molecule.  This 305 +16 peak was observed for all 
oxidized species and is indicative of oxidation occurring on the benzimidazole portion of 
the molecule.  Figure 28 illustrates the location of oxidation sites on R941000; however, 
due to the limited fragmentation of the parent compound it is hard to diagnose the exact 
location of biotransformation for each oxidized species.  There are many potential sites of 
oxidation ranging from the alkyl side chains to aromatic rings. 
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Figure 27.  The top figure is the chromatogram showing the XIC of the parent +16 metabolite at 
571.257 amu of the 2-4 h bile samples while the bottom shows the fragmentation pattern of the 
benzimidazole portion at 6.8 min. 
0 ppm 
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Figure 28.  Potential sites of oxidation and resultant fragmentation patterns are shown above. 
 Due to the unavailability of radiolabeled R941000 and telmisartan, a qualitative 
approach using integrated UV absorption peaks was employed to estimate the relative 
amount of metabolites.  UV peaks of parent and metabolites were integrated for each 
collection time and summed.  UV absorption is used rather than integrated mass spectra 
data due to differences in ionization efficiencies of various molecules.  A molecule that 
has relatively low abundance but easily ionizes may appear more intense through MS 
detection, than a highly abundant poorly ionizing molecule, giving a false impression of 
the relative amounts of ions.  UV absorption, though, is likely to be more consistent 
across parent and metabolite species than MS since they would contain similar 
chromophores and absorption would be more dependent on quantity. 
 Summation of all metabolite peak integrations was done for all bile samples and 
recorded in Table 4 for each sampling time.  The peaks observed at rt 5.68 and 6.28 min 
are the potential O-glucuronide and N-glucuronide, respectively.  The relative absorbance 
of N-glucuronide by UV absorption ranged from 47.2% at 2 h to 56.6 and 56.2 for 4 and 
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6 h samples, respectively. Similarly, relative O-glucuronide absorbance ranged from a 
high of 24.0% (6 h) to 52.8% at 2 h.  The peak at 6.84 min comprises both the parent and 
oxidized species since they were unable to be chromatographically resolved with the 
column conditions used while analyzing UV absorption. Parent and +16 metabolites 
abundance was 0.4% at the 2 h sample, but increased to 12.7% and 13.8% at 4 and 6 h, 
respectively.  An unknown peak at 5.4 min showed a relative abundance at 6.1% at 6 h.  
Table 4.  Metabolite % by UV peak area. 
UV Absorption Peak Area 
Metabolite Unknown O-glucuronide N-glucuronide Parent & +16 
Time 5.4 5.68 6.28 6.84 
0-2 h - 13454 12018 10.45 
2-4 h - 16451 30292 6794 
4-6 h 3712 14652 34203 8389 
total 
absorbance 
@ RT 
3712 44557 76513 15193 
0-2 h % 0 % 52.8 % 47.2 % 0.04 % 
2-4 h % 0 % 30.7 % 56.6 % 12.7 % 
4-6 h % 6.10 % 24.0 % 56.1 % 13.8 % 
3.2.1 In vitro Metabolism Studies 
 From characterizing the metabolite profile in rat bile, it was apparent 
glucuronidation plays an important role in R941000 metabolism and elimination; 
therefore, it was desirable to find in vitro systems that could be used to predict human 
metabolism.  Since many similarities between human and rat metabolism exist, an in 
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vitro assay that mimics rat in vivo results may correlate to in vivo human metabolism.   
Two commonly employed systems for in vitro studies are microsomes and cryopreserved 
hepatocytes.  Both hepatocytes and microsomes were used in the characterization of 
R941000 metabolism and will be discussed presently. 
3.2.2 Rat and Human Cryopreserved Hepatocyte and Microsomal Studies. 
 Hepatocytes contain all phase I and II enzymes as well as the necessary cofactors  
for their proper function, and are considered a benchmark for in vitro metabolism 
studies.14  For this reason, human and rat hepatocyte incubations were performed for in 
vitro assessment.  Since glucuronidation appeared to be a major route of metabolism, 
telmisartan was used as a positive control to test UGT1A activity in the hepatocytes.  
Both R941000 and telmisartan were incubated at 10 µM for 0, 0.5, 1, 2, and 4 h using the 
same lot of rat and human hepatocytes.  Samples were then analyzed using the Waters 
Xevo-G2 UPLC-QToF system for identification of metabolites.  It should be noted that 
both human and rat hepatocytes were used for each compound; however, they both gave 
similar results and only human or rat data will be given as examples. 
 Incubation of telmisartan in human and rat hepatocytes resulted in the formation 
of the telmisartan-O-acyl glucuronide with no other metabolites being observed.  Results 
are shown for human hepatocytes, and are given in Figure 29.  The XIC of 515.24 
(Figure 29 top) shows two peaks, one the parent (6.86 min), and presumably the in-
source fragment of telmisartan-O-acyl glucuronide (5.61 min).  Indeed, the mass 
fragment spectrum at 5.6 min yields a prominent ion of 691.275, with a mass error of 
2.17 ppm for the telmisartan-O-acyl glucuronide; moreover, the telmisartan fragment at 
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515.243 amu (8.35 ppm) and characteristic 305 amu fragment are shown in the bottom 
portion of Figure 29, confirming the presence of the glucuronide metabolite and activity 
of UGT1A in the hepatocytes.  
 
Figure 29.  Telmisartan incubated in HCH for 2 h. The chromatogram (top) shows the XIC of 
telmisartan [H+] with an acyl glucuronide peak and telmisartan peak.  The mass fragmentation 
peak (bottom) of the acyl glucuronide at 5.61 min shows ions corresponding to telmisartan-O-
acyl glucuronide [H+] and characteristic fragmentation pattern. 
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 Incubation of R941000 in human and rat hepatocytes yielded markedly different  
results from telmisartan.  There were no obvious glucuronide metabolites when extracting 
the parent MW ion from the total chromatogram; additionally an XIC of 731.29 amu 
revealed no glucuronidated metabolites (Figure 30 top left).  Analyzing the UV 
absorption of the spectrum revealed four peaks, with the parent at 6.6 min and three other 
minor peaks at 6.5, 6.2, and 5.8 min (Figure 30 top right).  From the mass spectrum of 
each metabolite, it was determined they correlated with +16 metabolites of R941000, 
with the 6.5 min peak at 4 h incubation given as an example (Figure 30 bottom left).  
Further analysis of the fragmentation revealed a 321 amu ion, indicating oxidation of the 
benzimidazole portion of the molecule (Figure 30 bottom right).  All peaks showed a 
similar fragmentation pattern, indicating oxidation occurs on the benzimidazole side of 
the molecule.  
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Figure 30.  Results from the incubation of 10 µM R941000 with HCH at 4 h shown above. An 
XIC for the R941000–glucuronide (top left), UV absorption spectrum (top right), a XIC of 571.25 
amu (bottom left), and mass fragmentation spectrum (bottom right) indicate only R941000 +16 
metabolites observed on the benzimidazole portion of the molecule. 
 Incubation of hepatocytes displayed similar oxidation metabolism as was  
observed in bile, yet no glucuronidated species were observed.  The hepatocytes did show 
UGT activity for telmisartan, so it was hypothesized there might be a permeability issue 
with R941000, either through passive mechanisms or an inability to be taken up by 
transporters.  Telmisartan is a substrate for hepatic organic anion transporting polypeptide 
(OATP) OATP 1B3, and functional transporters may have facilitated its uptake into the 
hepatocytes, exposing telmisartan to UGT1A, whereas R941000 may have lacked this 
ability.26  A method to expose R941000 to active UGT was desired to mimic the in vivo 
glucuronidation found in bile.  Microsomes pre-incubated with the pore forming 
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polypeptide, alamethicin, supplemented with UDPGA and NADPH, was the 
methodology chosen to increase microsomal UGT activity. 
A concentration of R941000 or telmisartan at 10 µM was incubated with 
alamethicin treated microsomes at a 1 mg/ml microsomal protein concentration with 
NADPH and UDPGA, respectively.  Incubations were carried out from 0 to 2 h, and 
metabolite formation was monitored using the API-4000 Qtrap LC-MS system.  Use of 
the triple quadrupole instead of the QToF was due to its excellent sensitivity and system 
availability.  Additionally, a shorter 5 min LC run was utilized. 
 Telmisartan once again served as a positive control, and results are recorded in        
Figure 31, where all MRM channels are shown in one chromatogram.  The red trace is 
that of the telmisartan MRM channel and the green trace is the acyl glucuronide 
metabolite.  As can be seen there are two telmisartan peaks; the earlier eluting peak is 
that of the acyl glucuronide metabolite that underwent in source fragmentation, and the 
latter, the parent compound.  Formation of the O-acyl glucuronide metabolite was 
confirmation that substrates such as telmisartan did indeed have access to the UGT 
enzymes and that at least UGT1A was active. 
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Figure 31.  The top chromatogram shows the incubation of 10 µM telmisartan in HLM at 2 h in 1 
mg/ml of microsomal protein treated with alamethicin.  The red trace is the MRM channel for 
telmisartan, and the green is that of the acyl-glucuronide metabolite. The bottom chromatogram 
shows the results for RLM. 
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R941000 was incubated in treated HLM with the results recorded in Figures 32 
and 33.  Figure 32 shows the incubation results at 0 h with only parent and internal 
standard ions observed.  Results at 2 h are given in Figure 33, where MRM channels 
for R941000, +16, and glucuronide metabolites are shown in top, middle, and bottom, 
respectively.  R941000 had an intensity of about 106 cps, about twice the intensity of 
the main oxidized peak at 2.5 min.  There were only two partially resolved peaks 
observed for +16 metabolites, one at 2.52 min, and the other at 2.45 min.  This is likely 
due to the use of a shorter column with larger particle size (3 µm compared to 1.7 µm) 
and lower flow rate leading to a loss of resolution between the different metabolites.  A 
glucuronidation metabolite appeared in its respective channel at 2.24 min; however, its 
relative abundance was low, with a peak intensity of approximately 2,000 cps.  
Moreover, only one peak was observed.
 
Figure 32.  MRM of R941000 and its glucuronide metabolite in alamethicin treated HLM at 
time 0.  MRM transitions for R941000 and IS (above), R941000 (middle), and glucuronide 
metabolite (bottom). 
63 
 
Figure 33.  The above chromatogram shows the MRM transitions for R941000 (top), R+16 
metabolites (middle), and the glucuronide metabolite transitions (bottom), with HLM at 2 h. 
 R941000 and telmisartan were incubated in alamethicin treated rat liver 
microsomes (RLM) under the same conditions as HLM (Figure 34); however, +16 
metabolites were noticed, but no glucuronidation products were observed.  Additionally, 
formation of oxidized species appeared anemic compared to HLM.  These results were 
confusing since metabolite profiling in bile indicated glucuronidation is an important 
metabolism pathway.  However, literature sources indicated that at low doses telmisartan 
is primarily metabolized in the gut, but UGT1A enzymes in the intestine get saturated at 
higher doses.25  Additionally, in vitro data indicated telmisartan displayed an affinity for 
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intestinal microsomes.  While limited in terms of capacity, the intestine does play an 
important role in telmisartan disposition at lower doses.  Since hepatic extraction 
experiments showed little metabolism in liver for R941000, it was postulated that the gut 
may be the primary location of glucuronidation.   
 
Figure 34.  Incubation of 10 µM R941000 in alamethicin treated RLM at the 2 h time point.  
Above is the chromatogram of R941000 transitions; middle, the glucuronide MRM transition, 
and bottom, the +16 metabolites. 
. 
 To test rat intestinal microsomal (RIM) activity, 10 µM R941000 was incubated 
in 1 mg/ml RIM protein treated with alamethicin in the same manner as RLM.  Results 
are given in Figure 35, where it can be seen that a single glucuronide peak was formed, in 
addition to +16 metabolites.  Like HLM, the relative abundance of glucuronides by mass 
spectroscopy appeared minimal, with only 1,500 cps being recorded.   
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Figure 35.  10 µM R941000 incubated in alamethicin treated RIM for 2 h.  The top 
chromatogram shows the parent R941000 channel, followed by the glucuronide (middle) and 
+16 metabolite (bottom) channels. 
 From the microsomal experiments, oxidation mechanisms appeared to be more 
relevant than glucuronidation activity, contrary to in vivo observations.  Relative 
abundance by mass spectroscopy can be deceptive due to ionization efficiencies; 
additionally, other microsomal products may be forming that were not caught with the 
monitored transitions.  To capture the importance of total phase I contribution to 
R941000 metabolism, microsomal stability assays were employed.  For microsomal 
stability assays, a compound’s disappearance over time is recorded and a half-life is 
established (see Equation 11).  In this way, all contributing factors can be accounted for, 
and the importance of phase I activity can be established. 
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 R941000 was incubated with HLM or RLM at 1 µM (reduced concentration to 
avoid saturation of enzymes) in 1 mg/ml protein over 45 min, with quenching times of 0, 
5, 15, 30, and 45 min.  Standards midazolam and propranolol were used for short and 
long stability controls (propranolol was metabolized quickly in rat; therefore, RLM 
lacked a long positive control).  Results are recorded in Figures 36 and 37 (HLM, RLM) 
where midazolam had a half-life of around 3.5 min in HLM and RLM and propranolol 38 
min in HLM and nearly 6 min in RLM.  R941000 appeared stable with a half-life 
exceeding 45 min for both human and rat liver microsomes. 
 
Figure 36.  The stability of R941000 in HLM 
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Figure 37.  The stability of R941000 in RLM 
 In vitro data had thus far failed to significantly correlate with in vivo results; 
however, a modified supplemented microsome protocol was attempted.  Several methods 
report improved UGT1A4 and UGT1A9 using 100 mM tris buffer pH 7.5-7.7 in human 
microsomes and expressed enzymes, while having no effect on other isoforms.17  Both of 
these enzymes are capable of N-glucuronidation and may thus provide a more vigorous 
metabolism of R941000.  While UGT1A4 and 1A9 are human UGTs (rodent homologs 
are inactive), it was hoped a change in buffer would result in improved R941000 
glucuronidation.  Results are shown in Figure 38 for the 2 h time points.  Telmisartan 
acyl glucuronide formation had peak intensities of 106 cps, while no glucuronidation was 
observed for R941000. 
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Figure 38.  Incubation of R941000 in alamethicin treated RLM with tris-buffer.  The two top 
chromatograms are the MRM transitions for telmisartan and its acyl glucuronide metabolite 
while the bottom two are of R941000 and its glucuronide metabolite. 
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4.0 Discussion 
Recently, our lab demonstrated the feasibility of using a tetrazolone group as a 
bioisostere of a carboxylic acid for a number of compounds including telmisartan.5  It 
was uncertain how replacement of this moiety with a tetrazolone would alter compound 
DMPK attributes.  Thus, PK and metabolism studies were performed on the telmisartan-
tetrazolone analog R941000 as an example of how disposition may be altered with this 
novel bioisostere. 
Pharmacokinetics 
 
 R941000 total exposure levels and half-life were approximately 1.5 fold greater 
than telmisartan, while clearance was reduced about 1.5 fold.  Volume of distribution for 
the two compounds was nearly identical, and bioavailability values were comparable at 
65% and 59% for R941000 and telmisartan, respectively.  
No significant hepatic first pass effect of R941000 was observed (HE <4%); 
however, telmisartan had an apparent HE of approximately 28%, and it was postulated 
that the lack of observed liver metabolism may partly explain the nearly threefold greater 
R941000 Cmax values given the similar bioavailability of the compounds. 
 No R941000 or telmisartan was found in urine after 24 h, indicating biliary 
excretion into feces remains the predominant route of elimination; however, only 40-50% 
of either compound was recovered in feces, likely correlating to the fraction of compound 
not absorbed.  Future studies with later time points are needed for a more definitive 
determination of excretion route. 
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Metabolism  
In vivo metabolism studies with rat bile indicated differences in metabolism 
between the two compounds.  Telmisartan is exclusively glucuronidated to an O-acyl 
glucuronide metabolite, while two major glucuronide metabolites were observed for 
R941000.  Given the lack of glucuronidation occurring on the benzimidazole portion of 
telmisartan, it was postulated that glucuronidation of R941000 was occurring on the 
tetrazolone portion of the molecule, and that both an N- and O-glucuronide were being 
formed.  Incubations with β glucuronidase in rat bile failed to eliminate the glucuronide 
peak preceding R941000 elution at 10.13 min, while the earlier eluting peak at 9.29 min 
disappeared, and an increase in peak intensity of R941000 was observed.  Taken together, 
these results suggest a possible N-glucuronide at 10.13 min and O-glucuronide at 9.29 
min.  According to UV spectroscopy the alleged N-glucuronide and O-glucuronide made 
up 55% and 32% of all observed parent and metabolite species, respectively. 
 Glucuronidation of a tetrazolone as opposed to a carboxylic acid may have 
positive consequences, since carboxylic acids can form potentially toxic acyl 
glucuronides.  Glucuronidated tetrazolone metabolites may be less prone to react with 
nucleophilic amino acid residues, which modify endogenous proteins, than their acyl 
glucuronide counterparts.  As previously discussed, acyl glucuronides are capable of 
undergoing trans-acylation or acyl migration followed by ring opening and a subsequent 
Schiff-base reaction (see Figure 8) with electron rich amino acids.10  Figures 39, 40, and 
41 propose potential analogous acyl glucuronide reactivity pathways a tetrazolone 
glucuronide may undergo with nucleophilic amino acid residues. 
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Figure 39.  The potential of an N-glucuronidated tetrazolone to undergo tetrazolone migration is 
shown (top) along with its susceptibility to nucleophilic attack at the carbonyl (bottom). 
Figure 39 depicts the likely inactivity of N-glucuronidated tetrazolones towards 
nucleophiles.  Factors such as poor electrophilicity of the tetrazolone carbonyl (due to the 
donation of electrons from adjacent nitrogen atoms and the overall aromaticity of the 
tetrazolone) would make tetrazolones a poor candidate for nucleophilic attack.  
Moreover, the nitrogen glucuronide makes a poor leaving group, further reducing the 
likelihood of a direct nucleophilic attack on the tetrazolone carbon (depicted in the 
bottom of Figure 39 for a tetrazolone and urea as a “similar” carbonyl).  For these same 
reasons, migration of the glucuronide around the tetrazolone would be unlikely as well; 
however, if the hydroxyl group on the 2 carbon of the glucuronide managed to attack the 
tetrazolone carbonyl, a five membered ring intermediate could form.  The likelihood of 
this intermediate proceeding to another product is again improbable, since it would 
involve cleaving the nitrogen-carbon bond and forming an eight membered ring.    
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 Figure 40 illustrates a possible mechanism for an O-tetrazolone glucuronide 
migration and Schiff-base reaction.  The hydroxyl group on C2 may attack the 
tetrazolone carbonyl, forming a 5 member ring intermediate and allowing for a 
subsequent migration around the glucuronide.  The glucuronide can alternate between 
closed and open forms, making it susceptible to a nucleophilic amino acid residue. 
 
Figure 40.  The potential toxicity of O-glucuronides through tetrazolone migration, ring opening, 
and glycation are shown. 
 There exists the possibility of a direct nucleophilic attack of O-glucuronide 
tetrazolones at the anomeric carbon of the glucuronide, the mechanism of which is shown 
in Figure 41.  As can be seen, the anomeric carbon may be liable to nucleophilic amino 
acid residues; additionally, the tetrazolone would make a good leaving group, resulting in 
a glucuronidated protein.  However, the only examples of trans-acylation occurring in 
literature happen on the carbonyl portion of the molecule, and it is uncertain at this point 
if the anomeric carbon would indeed be susceptible to nucleophilic attack.10 
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Figure 41.  The potential reactivity of O-glucuronidated tetrazolone via glucuronidation is shown 
above. 
 While N-glucuronides may be unreactive to endogenous nucleophilic amino acids, 
the O-tetrazolone glucuronide could potentially possess a similar reactivity to that of an 
acyl glucuronide.  Future studies incubating O- and N-glucuronide tetrazolones with 
nucleophiles mimicking in vivo conditions, such as thiols, may provide evidence 
confirming the liability (or lack thereof) of tetrazolones towards nucleophilic amino acid 
residues. 
 Various attempts to replicate in vivo metabolism in an in vitro assay failed to 
generate any significant amounts of tetrazolone glucuronides, though some oxidized 
metabolites were observed.  Attempts at enhancing microsomal UGT with alamethicin 
yielded no R941000-glucuronide metabolites.  With the lack of hepatic extraction 
observed, yet significant in vivo observation of glucuronide metabolites, it was thought 
glucuronidation may occur in the gut rather than the liver; however, incubation with 
alamethicin treated intestinal microsomes did not result in significant levels of 
glucuronidated metabolites, while those incubated with telmisartan did.  Overall P450 
contribution appeared minimal in vitro as well, with both telmisartan and R941000 
showing microsomal stability > 45 min. 
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Conclusion 
 PK and metabolism analysis confirmed R941000 maintained similar to slightly 
improved PK profile in rat, while differing in metabolism with the formation of two 
major glucuronide metabolites.  It is hypothesized that these glucuronides are an N-
glucuronide and O-glucuronide.  In vitro assays were unable to mimic in vivo results, and 
it is unclear where and what UGT isozyme is responsible for R941000 glucuronidation in 
vivo. 
While only one compound and one preclinical species were assessed in this study, 
analysis of R941000 does provide a useful first step in demonstrating the feasibility of 
replacement of carboxylic acids with tetrazolones.   
5.0 Future Studies 
 Currently, development of an in vitro assay mimicking in vivo results of R941000 
glucuronidation is needed.  Future studies using UGT expressed enzymes are planned to 
address this issue.  UGT expressed enzymes may provide more robust UGT activity and 
will allow for identification of individual UGT isozymes responsible for glucuronidation 
if observed, thus potentially determining what enzyme(s) are responsible for the N- or O-
glucuronide.  Additionally, identification of the human recombinant UGT enzyme(s) may 
provide for a better understanding of potential human metabolism as well as potential 
drug-drug interactions. While an N- and O-glucuronide are the suspected metabolites, 
further characterization of these species is needed to definitively confirm their identity.  
Chemical synthesis of the proposed metabolites is being attempted and isolation of the 
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observed metabolites in sufficient quantities in bile for NMR analysis are currently 
underway.  
Determining potential reactivity mechanisms of a compound or particular 
molecular moiety can be a long and arduous process, and one that sometimes may only 
become evident after a compound has been on the market for a number of years.10-12  
Indeed, much time, energy, and research have gone into developing the current 
hypothesis of acyl glucuronide toxicity.10  However, there are a few assays that may be 
employed to test if tetrazolone glucuronides may be prone to interact with endogenous 
proteins in the same manner as acyl glucuronides. One method, as previously suggested, 
would be to incubate tetrazolone glucuronides with nucleophiles to assess their 
susceptibility to nucleophilic attack.  A second method, developed by Sawamura and co-
workers, correlates reactivity of acyl glucuronides with its stability in a buffer solution 
and its tendency towards acyl migration.  The shorter the half-life, the more prone an acyl 
glucuronide is to migrate and react with electron rich amino acids.12  In this paper, 
Sawamura tested several O-acyl glucuronide metabolites for compounds such as 
zomepirac (short half-life), diclofenac (intermediate half-life) and telmisartan (long half-
life).  Compounds forming acyl glucuronides with short half-lives were strongly 
correlated with toxicity and subsequent market withdrawal; those with intermediate half-
lives were associated with warnings; those with good stability were considered “safe.”12  
Synthesizing O- and N-glucuronide equivalents to compounds such as zomepirac, 
diclofenac, and telmisartan acyl glucuronides and testing their stability in buffer may 
provide an informative method of assessing potential reactivity and ranking of 
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tetrazolone glucuronides relative to each other and their acyl glucuronide counterparts.12 
Additionally, the stability of N-glucuronides may help confirm its inability for tetrazolone 
migration. Finally, animal studies comparing toxicity between tetrazolones and 
carboxylic compounds may provide a general yet informative study on the relative 
toxicity of this bioisostere to its carboxylic acid counter parts. 
While the R941000 tetrazolone analog of telmisartan has thus far behaved as a 
carboxylic acid bioisostere, analysis of additional tetrazolone analogs is needed to better 
characterize this moiety as a carboxylic acid replacement since other tetrazolone analogs 
may have a different disposition and potency relative to their carboxylic acid 
counterparts.  A larger set of examples would provide greater context into the range of 
disposition alterations caused by this bioisostere. 
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